Part 1 will discuss the recent FDA approvals of two new sickle cell disease treatments. We will also discuss value assessments and their importance for new treatments emerging on the market.
Part 1 will discuss the recent FDA approvals of two new sickle cell disease treatments. We will also discuss value assessments and their importance for new treatments emerging on the market.